文献速递肝病

美国脂肪性肝病相关全因及病因特异性死亡率

Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
PubMed 文献 · Aliment Pharmacol Ther · 2024-04-22

基于第三次美国国家健康与营养调查的7811名个体及截至2019年的死亡随访数据,比较脂肪性肝病(SLD)及其亚型、代谢功能障碍相关脂肪性肝病(MAFLD)与非酒精性脂肪性肝病(NAFLD)对全因及病因特异性死亡率的影响。中位随访27.1年,SLD、MAFLD和代谢功能障碍相关脂肪性肝病(MASLD)均与全因死亡率升高相关,MetALD亚型全因和癌症相关死亡风险更高。

要点

  • SLD与全因死亡风险升高相关(HR 1.15,95%CI 1.02-1.29)。
  • MetALD全因死亡HR 1.68(95%CI 1.10-2.57),癌症死亡HR 2.40(95%CI 1.23-4.66)。
  • MASLD伴进展性纤维化较不伴进展性纤维化者全因死亡风险升高。

核心结论

  • 在美国成年人中,SLD尤其是MASLD和MetALD与全因死亡率升高相关。
  • 采用提出的SLD标准可能有助于识别全因死亡风险升高的SLD个体。

研究设计与样本

  • 研究纳入第三次美国国家健康与营养调查的7811名个体,并链接截至2019年的死亡数据进行分析。
  • SLD基于超声肝脂肪变性定义,SLD亚型及MAFLD采用提出的定义,使用Cox比例风险模型评估全因及病因特异性死亡率。

主要发现

  • 中位随访27.1年,SLD全因死亡HR 1.15(95%CI 1.02-1.29),MAFLD全因死亡HR 1.23(95%CI 1.09-1.38),MASLD全因死亡HR 1.13(95%CI 1.01-1.27)。
  • MetALD全因死亡HR 1.68(95%CI 1.10-2.57),癌症相关死亡HR 2.40(95%CI 1.23-4.66)。
  • MASLD伴进展性纤维化者较MASLD不伴进展性纤维化者全因死亡风险升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, a panel of multi-society experts proposed steatotic liver disease (SLD) as an alternative terminology for metabolic dysfunction-associated fatty liver disease (MAFLD) or nonalcoholic fatty liver disease (NAFLD). AIMS: We compared the impact of SLD, subtype of SLD, MAFLD and NAFLD on all-cause and cause-specific mortality. METHODS: A total of 7811 individuals in the third National Health and Nutrition Examination Survey and linked mortality through 2019 were analysed. SLD was defined based on ultrasonographic hepatic steatosis. SLD, subtype of SLD and MAFLD were defined using the proposed definitions. The Cox proportional hazard model assessed all-cause/cause-specific mortality. RESULTS: During a median follow-up of 27.1 years, individuals with SLD and MAFLD experienced approximately 13%-23% higher risk of all-cause mortality (hazard ratio [HR]: 1.15, 95% confidence interval [CI]: 1.02-1.29 for SLD; HR: 1.23, 95% CI: 1.09-1.38 for MAFLD; HR: 1.13, 95% CI: 1.01-1.27 for metabolic dysfunction-associated steatotic liver disease [MASLD]). Individuals with MetALD demonstrated a higher risk of all-cause (HR: 1.68, 95% CI: 1.10-2.57) and cancer-related mortality (HR: 2.40, 95% CI: 1.23-4.66). MASLD with advanced fibrosis had an increased risk of all-cause mortality compared to MASLD without advanced fibrosis. CONCLUSIONS: SLD, especially MASLD and MetALD, is associated with increased all-cause mortality among adults in the US. Given this significant association between SLD or subtype of SLD (MASLD and MetALD) and all-cause mortality, adopting the proposed SLD criteria may help identify a sub-group of individuals with SLD who are at an increased risk for all-cause mortality.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kim D, Wijarnpreecha K, Cholankeril G, et al. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States. Aliment Pharmacol Ther. 2024. PMID: 38649335. doi:10.1111/apt.18011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。